Sensei Biotherapeutics (SNSE) Competitors $0.45 -0.01 (-2.16%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends SNSE vs. TXMD, SCYX, OSTX, OCX, IMMX, UNCY, IMNN, ACHL, CERO, and ANEBShould you be buying Sensei Biotherapeutics stock or one of its competitors? The main competitors of Sensei Biotherapeutics include TherapeuticsMD (TXMD), SCYNEXIS (SCYX), OS Therapies (OSTX), OncoCyte (OCX), Immix Biopharma (IMMX), Unicycive Therapeutics (UNCY), Imunon (IMNN), Achilles Therapeutics (ACHL), CERo Therapeutics (CERO), and Anebulo Pharmaceuticals (ANEB). These companies are all part of the "pharmaceutical products" industry. Sensei Biotherapeutics vs. TherapeuticsMD SCYNEXIS OS Therapies OncoCyte Immix Biopharma Unicycive Therapeutics Imunon Achilles Therapeutics CERo Therapeutics Anebulo Pharmaceuticals TherapeuticsMD (NASDAQ:TXMD) and Sensei Biotherapeutics (NASDAQ:SNSE) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, risk, earnings, profitability, community ranking, dividends, valuation and analyst recommendations. Do analysts rate TXMD or SNSE? Sensei Biotherapeutics has a consensus price target of $4.33, suggesting a potential upside of 855.53%. Given Sensei Biotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Sensei Biotherapeutics is more favorable than TherapeuticsMD.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TherapeuticsMD 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Sensei Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer TXMD or SNSE? In the previous week, TherapeuticsMD had 6 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 8 mentions for TherapeuticsMD and 2 mentions for Sensei Biotherapeutics. Sensei Biotherapeutics' average media sentiment score of 0.94 beat TherapeuticsMD's score of 0.07 indicating that Sensei Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TherapeuticsMD 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Sensei Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher earnings and valuation, TXMD or SNSE? TherapeuticsMD has higher revenue and earnings than Sensei Biotherapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTherapeuticsMD$1.30M12.42-$10.28MN/AN/ASensei BiotherapeuticsN/AN/A-$34.10M-$1.19-0.38 Does the MarketBeat Community favor TXMD or SNSE? TherapeuticsMD received 359 more outperform votes than Sensei Biotherapeutics when rated by MarketBeat users. However, 79.41% of users gave Sensei Biotherapeutics an outperform vote while only 59.48% of users gave TherapeuticsMD an outperform vote. CompanyUnderperformOutperformTherapeuticsMDOutperform Votes38659.48% Underperform Votes26340.52% Sensei BiotherapeuticsOutperform Votes2779.41% Underperform Votes720.59% Which has more risk and volatility, TXMD or SNSE? TherapeuticsMD has a beta of 1.14, suggesting that its share price is 14% more volatile than the S&P 500. Comparatively, Sensei Biotherapeutics has a beta of 0.06, suggesting that its share price is 94% less volatile than the S&P 500. Is TXMD or SNSE more profitable? Sensei Biotherapeutics has a net margin of 0.00% compared to TherapeuticsMD's net margin of -207.77%. TherapeuticsMD's return on equity of -14.08% beat Sensei Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets TherapeuticsMD-207.77% -14.08% -9.61% Sensei Biotherapeutics N/A -48.14%-42.01% Do insiders and institutionals hold more shares of TXMD or SNSE? 30.7% of TherapeuticsMD shares are owned by institutional investors. Comparatively, 10.5% of Sensei Biotherapeutics shares are owned by institutional investors. 2.3% of TherapeuticsMD shares are owned by company insiders. Comparatively, 22.0% of Sensei Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryTherapeuticsMD beats Sensei Biotherapeutics on 8 of the 15 factors compared between the two stocks. Ad Golden CrestBuffett’s Selling Out: Is Your 401(k) About to Get Wiped Out?Let me share something important with you. Just a few weeks ago, Warren Buffett unloaded $932 million worth of bank stocks. He didn't do it on a whim—he knows something big is coming. The question is: Why aren't you taking action, too?Click Here For Your Free Guide Get Sensei Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SNSE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNSE vs. The Competition Export to ExcelMetricSensei BiotherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.41M$6.39B$5.06B$8.67BDividend YieldN/A8.04%5.06%4.06%P/E Ratio-0.3810.63100.7117.26Price / SalesN/A266.481,206.6171.28Price / CashN/A53.4940.7536.36Price / Book0.179.306.325.87Net Income-$34.10M$154.14M$119.47M$225.66M7 Day Performance-18.44%-9.49%-5.11%-1.34%1 Month Performance-1.20%-7.23%-3.21%1.00%1 Year Performance-21.81%30.70%32.43%25.27% Sensei Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNSESensei Biotherapeutics4.7274 of 5 stars$0.45-2.2%$4.33+855.5%-25.0%$11.41MN/A-0.3840Upcoming EarningsNews CoverageGap DownHigh Trading VolumeTXMDTherapeuticsMD0.7285 of 5 stars$1.40-4.1%N/A-40.7%$16.14M$1.30M0.00420Analyst ForecastShort Interest ↑News CoverageSCYXSCYNEXIS2.4257 of 5 stars$1.20-4.8%N/A-27.7%$45.54M$140.14M-1.6260Positive NewsOSTXOS TherapiesN/A$2.20flatN/AN/A$44.11MN/A0.00N/ANews CoverageGap UpOCXOncoCyte1.6689 of 5 stars$2.61-6.8%$4.42+69.2%-34.1%$43.94M$1.02M0.00120Earnings ReportAnalyst ForecastGap DownIMMXImmix Biopharma3.0792 of 5 stars$1.59-1.9%$7.00+340.3%-64.3%$43.74MN/A-1.879Earnings ReportUNCYUnicycive Therapeutics3.3065 of 5 stars$0.46+2.2%$5.13+1,014.1%-12.0%$43.40M$680,000.00-0.479Analyst ForecastAnalyst RevisionIMNNImunon2.7031 of 5 stars$0.72-4.0%$12.00+1,565.3%-25.7%$43.28M$500,000.00-0.3833Short Interest ↑Analyst RevisionACHLAchilles Therapeutics2.546 of 5 stars$1.05-1.9%$4.00+281.0%+31.1%$43.14MN/A-0.66250Short Interest ↓News CoverageCEROCERo TherapeuticsN/A$0.29+54.0%N/AN/A$42.88MN/A0.008Insider SellingShort Interest ↑News CoverageGap UpHigh Trading VolumeANEBAnebulo Pharmaceuticals3.1 of 5 stars$1.59+4.6%$8.00+403.7%-28.8%$41.19MN/A-5.294Short Interest ↓News CoverageGap Up Related Companies and Tools Related Companies TXMD Alternatives SCYX Alternatives OSTX Alternatives OCX Alternatives IMMX Alternatives UNCY Alternatives IMNN Alternatives ACHL Alternatives CERO Alternatives ANEB Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SNSE) was last updated on 11/16/2024 by MarketBeat.com Staff From Our PartnersThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredBuffett’s Selling Out: Is Your 401(k) About to Get Wiped Out?Let me share something important with you. Just a few weeks ago, Warren Buffett unloaded $932 million worth of...Golden Crest | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sensei Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sensei Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SNSE Stock Alerts